Publications, Pharmaceutical

Why it is time to think differently about Nasal delivery of Biologics

COVID-19 has reinvigorated interest in the advantages of nasal delivery for a pharmaceutical industry already embracing a shift towards biologics.

This article considers the challenges and potential benefits of combining the two. The nasal delivery of biologics offers considerable potential for both local and systemic action and for direct access to the brain and CNS to address currently unmet therapeutic need. The unique features of biologics are discussed with reference to the associated difficulties of nasal delivery and the benefits of partnership with experts such as Aptar Pharma is highlighted. Work on the development of vaccines and prophylactics for COVID-19 illustrates what is achievable.

Download Publication
Author(s): Gemma Budd Irene Rossi
4 Apr 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

9 Jun 2022

Aptar Pharma discusses digital therapeutics for chronic conditions

Publications, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation

Read More
16 May 2022

Healthcare Packaging: The Future of Medical Devices

Publications, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation

Read More
25 Apr 2022

Nasal Drug Development, Trends and Challenges with Nasal Formulations

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
22 Apr 2022

Nose to Brain Drug Delivery – A Promising Future

Webinars, Pharmaceutical, Product Solutions, Device Innovations, Brand Differentiation, Market Insights

Read More
1 … 12 13 14 15 16 … 27

How Can We Help?

Back To Top